المؤلفون: Heine RJSD; Erasmus School of Health Policy and Management (ESHPM), Erasmus University Rotterdam, Rotterdam, The Netherlands; Erasmus Center for Health Economics Rotterdam (EsCHER), Erasmus University Rotterdam, Rotterdam, The Netherlands. Electronic address: heine@eshpm.eur.nl., Mathijssen RHJ; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands., Verbeek FAJ; Erasmus School of Health Policy and Management (ESHPM), Erasmus University Rotterdam, Rotterdam, The Netherlands., Van Gils C; IQVIA, Rotterdam, The Netherlands., Uyl-de Groot CA; Erasmus School of Health Policy and Management (ESHPM), Erasmus University Rotterdam, Rotterdam, The Netherlands; Erasmus Center for Health Economics Rotterdam (EsCHER), Erasmus University Rotterdam, Rotterdam, The Netherlands.

المصدر: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2024 Jun 21. Date of Electronic Publication: 2024 Jun 21.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 100883818 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1524-4733 (Electronic) Linking ISSN: 10983015 NLM ISO Abbreviation: Value Health Subsets: MEDLINE

المؤلفون: Haj Mohammad SF; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands. s.f.haj_mohammad@lumc.nl., Timmer HJL; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Zeverijn LJ; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Geurts BS; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Spiekman IAC; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Verkerk K; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Verbeek FAJ; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Verheul HMW; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Voest EE; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.

المصدر: Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2024 May 23; Vol. 63, pp. 368-372. Date of Electronic Publication: 2024 May 23.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Medical Journals Sweden AB Country of Publication: Sweden NLM ID: 8709065 Publication Model: Electronic Cited Medium: Internet ISSN: 1651-226X (Electronic) Linking ISSN: 0284186X NLM ISO Abbreviation: Acta Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Neoplasms*/drug therapy , Neoplasms*/genetics , Precision Medicine*/methods, Humans ; Netherlands ; Immunotherapy/methods ; Medical Oncology/methods ; Medical Oncology/trends ; Piperazines/therapeutic use ; Pyridines/therapeutic use ; Nivolumab/therapeutic use ; Antineoplastic Agents/therapeutic use ; Molecular Targeted Therapy/methods